BNP Paribas Financial Markets
DMAAR icon

BNP Paribas Financial Markets’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

BNP Paribas Financial Markets’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.2K Hold
119,686
– – ﹤0.01% 5340
2026
Q1 		$7.18K Hold
119,686
– – ﹤0.01% 5271
2025
Q4 		$22.4K Buy
+119,686
New +$23.2K ﹤0.01% 4986

Other funds holding DMAAR

Polar Asset Management Partners
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Clear Street
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
Highbridge Capital Management
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
Boothbay Fund Management
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

BNP Paribas Financial Markets's DMAAR Position: Q2 2026 in Review

BNP Paribas Financial Markets held its Drugs Made In America Acquisition Corp Rights (DMAAR) position steady in Q2 2026 at 119,686 shares worth $13.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5340.

BNP Paribas Financial Markets first reported a position in DMAAR in Q4 2025 and has held it in 3 quarters since. The position peaked at $22.4K in Q4 2025. 28 funds tracked by Wall St. Rank hold DMAAR as of Q2 2026.

  • BNP Paribas Financial Markets held 119,686 shares of Drugs Made In America Acquisition Corp Rights worth $13.2K as of Q2 2026.
  • BNP Paribas Financial Markets left its Drugs Made In America Acquisition Corp Rights share count unchanged in Q2 2026.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5340 holding.
  • BNP Paribas Financial Markets first reported a position in Drugs Made In America Acquisition Corp Rights in Q4 2025 and has held it in 3 quarters since.
  • BNP Paribas Financial Markets's Drugs Made In America Acquisition Corp Rights position peaked at $22.4K in Q4 2025.
  • 28 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.